Against this background, highlighting the involvement of this set of miRNAs in central and peripheral regulation of metabolic pathways, we presently analyzed them at baseline in plasma of T2D patients being subjected to GLP1-RA treatment and followed-up for a period of up to 12 months. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.